History
Salivary gland tumors have long drawn people's attention in the form of "a lump that can be felt below the ear or under the jaw." In the past, when such a lump developed, it was difficult to tell whether it was inflammation or a tumor, and even when surgery was performed, treatment outcomes were inconsistent because of bleeding, infection, and the limitations of anesthesia. In particular, the parotid gland is a large gland located on the side of the face, and the facial nerve, which produces facial expressions, passes through it in several branches, so nerve damage easily occurred when a tumor was removed. Initially, many took the approach that "removing the lump is the end of it," but over time, determining "the extent of resection that reduces recurrence while preserving the nerve" became the key challenge.
In the 20th century, as surgical anatomy became more refined and surgical instruments and hemostasis techniques advanced, techniques for identifying and preserving the nerve became standardized. In addition, as pathological diagnosis using the microscope advanced, it became established that salivary gland lumps that look similar on the outside are in fact divided into a very wide variety of tumors (benign and malignant). The big change here was that salivary gland tumors, once viewed as "a single disease," became clinically established as actually being a group of several diseases, each with different characteristics and treatments.
Advances in imaging were also decisive. Ultrasound (US) made it possible to check the location and shape of a mass relatively simply, and CT and MRI made it possible to predict before surgery whether a tumor had spread deep and how close it was to the surrounding bone, muscle, and nerves. As fine-needle aspiration (FNA) became widespread, the approach of estimating to some degree, even before surgery, "whether it is likely benign or likely malignant" and planning treatment accordingly became widely established. In other words, whereas in the past "if there is a lump, operate," the approach has now developed into "identify its nature with imaging and biopsy, and decide on treatment considering nerve preservation and prevention of recurrence."
Causes
It is difficult to state the cause of salivary gland tumors definitively as a single factor. In many cases, a clear cause cannot be identified at the individual level, and it is likely that several risk factors acted in combination. Moreover, because masses (lumps) that develop in the salivary glands tend to be benign more often, it is more practical to accurately determine "what the nature of this lump is" than to "trace its cause."
The risk factor most commonly mentioned is radiation exposure. There are reports that the risk of salivary gland tumors may increase in people who have previously received radiation therapy to the head and neck area, or in people who are likely to be exposed to radiation occupationally or environmentally. Smoking is not linked to all salivary gland tumors, but its association with certain benign tumors such as Warthin tumor is frequently mentioned. Some studies also suggest a possible association with exposure to chemicals such as dust, metals, and solvents in certain industrial environments, but it is difficult for an individual to determine the cause of their own tumor.
There are two key points in the section on causes. First, tumors can develop even when there are no clear risk factors. Second, even when risk factors are present, most people do not develop tumors. Therefore, the "management of causes" one can do in daily life realistically comes close to reducing unnecessary radiation exposure, maintaining healthy habits including not smoking, and being evaluated without delay if a newly developed lump does not go away.
Genetic Epidemiology
Salivary gland tumors are not widely known as "a disease in which family history plays a strong role." That is, just because someone in the family has had a salivary gland tumor, it is difficult to consider that the same disease will definitely develop in oneself. However, because tumors are by nature diseases that arise as the genetic information of cells changes, several genetic changes are involved in salivary gland tumors as well. The important distinction is between "inherited (changes passed down from birth)" and "acquired (changes that occur in cells during life)." In salivary gland tumors, acquired changes are more often clinically relevant.
There are many different kinds of salivary gland tumors, and each kind can start from a different cell. That is why genetic epidemiology has developed in the direction of summarizing "which molecular features are common in which subtypes." For example, specific gene rearrangements are observed in some cases of pleomorphic adenoma, and in mucoepidermoid carcinoma, specific gene fusions are known to aid diagnosis. Such information can be used to classify more accurately when the pathological diagnosis is ambiguous, or can serve as a supplementary clue for estimating the tumor's characteristics (likelihood of recurrence, aggressiveness).
The statement "there is a genetic change" does not immediately mean "it is a hereditary disease." Many genetic changes in tumors are found only within that tumor tissue and do not mean they are passed on directly to family members. In actual practice, imaging such as ultrasound (US) and biopsy usually come first, and genetic and molecular tests are often performed additionally when the pathology results are unclear or the choice of treatment is complicated. In summary, salivary gland tumors are not a disease centered on family history, but molecular-level information is becoming an increasingly important tool for accurate classification and choice of treatment.
General Epidemiology
Salivary gland tumors are relatively rare even among head and neck tumors as a whole. The salivary glands are divided into the major salivary glands (parotid, submandibular, and sublingual glands) and the minor salivary glands distributed throughout the mucous membranes of the mouth. Tumors arise most often in the parotid gland, and parotid tumors are known to have a relatively high proportion of benign tumors. Conversely, the proportion of malignancy tends to be higher in the submandibular gland, sublingual gland, and minor salivary glands, so even within the same "salivary gland tumor," the location is a clinically important clue.
They are often found from middle age onward, but certain subtypes can also occur at younger ages. Sex differences vary by tumor type, and environmental factors can also play a role, for example with tumors associated with lifestyle habits (e.g., smoking) being observed more commonly in men. The apparent differences in incidence between countries and regions are because not only ethnic differences but also environmental exposures, smoking rates, access to medical care, and differences in diagnostic and recording methods all have an influence.
The epidemiological message worth remembering for the general public is the "pattern" rather than the "numbers." First, many salivary gland tumors grow slowly and are painless, so their discovery may be delayed. Second, when the likelihood of malignancy increases, warning signs such as pain, rapid growth, skin changes, enlarged lymph nodes, and especially facial nerve paralysis may accompany the tumor. Therefore, in daily life, the fact that "a persistent lump requires evaluation" is more important than the fact that salivary gland tumors are a rare disease.
Pathogenesis
The salivary gland is a complex organ made up of secretory cells that produce saliva, the cells of the ducts through which saliva flows, and the supporting tissue that surrounds them. Because the shape and characteristics of a tumor differ depending on which of these cells it starts from, salivary gland tumors tend to be unusually diverse compared with those of other organs. The key to pathogenesis is that normal cells lose the rules that regulate growth and division and begin to proliferate without stopping.
Benign tumors generally grow slowly, have relatively distinct borders, and tend not to invade deeply into surrounding tissue. However, even benign tumors can cause facial asymmetry or discomfort if they keep growing, and some can recur if surgery is incomplete. In addition, though rare, cases have been reported in which a long-standing benign tumor turns malignant. Malignant tumors may invade surrounding tissue or spread to the lymph nodes and other organs. In particular, because the facial nerve passes through the inside of the parotid gland, if a tumor compresses or invades the nerve, the function of the facial muscles can decline.
At the cellular level, changes in genetic information are central. When genes that promote cell division are excessively switched on, genes that should suppress it are broken, or certain genes become abnormally joined, cells can overproliferate. It has been suggested that radiation exposure, chronic inflammation, tissue damage, and the like may promote such changes, but it is usually difficult to identify "exactly when it began" in an individual patient. Therefore, pathogenesis provides background knowledge for understanding treatment, but in actual practice, confirming the current extent and nature of the tumor with imaging and biopsy comes first.
Symptoms
The most common symptom of a salivary gland tumor is a lump in the area of a salivary gland. People often notice a lump gradually growing below the ear (parotid gland), under the jaw (submandibular gland), under the tongue (sublingual gland), or in minor salivary gland areas such as the palate or the inside of the cheek. It is common for there to be no pain and no skin changes, so some are discovered only after being watched for several months or more. However, because "a new lump that does not go away" needs to be distinguished from simple inflammation, evaluation is recommended.
Pain does not necessarily mean malignancy, but it can be an important clue. If the tumor irritates a nerve or is accompanied by surrounding inflammation, it can be painful, and tenderness may develop when it is pressed. If the passage through which saliva exits is blocked, there may be a feeling of swelling and worsening pain during meals; because such cases can be accompanied by obstruction or inflammation of the salivary duct, differentiation is needed. When salivary gland function declines, dry mouth, decreased saliva secretion, and a sticky feeling in the mouth may appear.
Symptoms that raise greater suspicion of malignancy include rapid increase in size, persistent and progressively worsening pain, nerve symptoms such as decreased sensation or numbness, difficulty opening the mouth (trismus), and difficulty chewing and swallowing (dysphagia). Above all, if facial nerve dysfunction newly appears, such as one side of the face drooping, difficulty closing the eye, or asymmetry of the corners of the mouth, it should be regarded as an important warning sign requiring prompt evaluation.
Signs
Signs refer to the objective findings a physician confirms on examination. The most basic step for salivary gland tumors is palpation. The physician checks whether the lump moves easily under the skin, whether it is firm, whether its surface is smooth, and whether it feels attached and fixed to the surrounding tissue. Generally, if it moves easily and its borders are relatively distinct, it is likely to be benign, but there are exceptions, so a conclusion cannot be drawn from this finding alone.
An important sign that raises suspicion of malignancy is facial nerve paralysis. Because the facial nerve passes through the parotid gland, if a tumor invades or strongly compresses the nerve, the facial muscles may become weak. In addition, if there are changes in the skin such as redness, ulceration, depression, or firm infiltration, an advanced lesion is suspected. Enlarged lymph nodes that can be felt in the neck are also an important clue, and the possibility of metastasis is evaluated while distinguishing them from simple inflammatory lymph nodes.
Minor salivary gland tumors may appear as a localized bulge of the oral mucosa or as a sore (ulcer) that does not heal well. Tumors around the sublingual gland may cause the floor of the mouth to swell and make tongue movement uncomfortable. Therefore, the examination is carried out not by looking only at the area of the lump, but by checking the entire oral cavity and the neck lymph nodes as well.
Screening
Standard screening tests performed regularly on the entire population are generally not recommended for salivary gland tumors. This is because the disease itself is relatively rare, a considerable number of the tumors are benign, and there is insufficient evidence that screening reliably lowers mortality. Instead, screening in a practical sense is closer to "being evaluated quickly when there are symptoms and signs."
The most important screening method is one's own observation. Seeking medical care helps with early detection if a new lump below the ear or under the jaw persists for 2 weeks or more or gradually grows larger, if it is accompanied by pain, sensory abnormalities, or skin changes, or if the movement of one side of the face changes. In some cases, a mass in the mouth is discovered incidentally during dental or ear, nose, and throat care, so regular oral checkups can indirectly be helpful.
Among tests, ultrasound (US) is often used as "an initial evaluation close to screening." It involves no radiation exposure, is relatively simple, and can determine whether a lump is a cyst (fluid-filled sac) or solid (firm tissue), as well as its size and borders. However, the type of tumor cannot be confirmed with ultrasound alone, and it has limitations in evaluating deep lesions or invasion of surrounding areas, so CT or MRI, and biopsy, may be needed. It is appropriate to understand screening for salivary gland tumors as the realistic combination of "symptom-based + initial ultrasound evaluation."
Diagnosis
Diagnosis begins with taking the medical history and a physical examination. The physician checks when the lump appeared, how quickly its size has changed, whether there is pain, whether swelling or pain worsens in relation to meals, whether there is dry mouth, and whether facial movement has changed. On examination, the location, size, firmness, and fixation of the lump, skin changes, lesions in the mouth, the neck lymph nodes, and facial nerve function (closing the eyes, movement of the corners of the mouth, etc.) are systematically evaluated.
Imaging is key to determining the extent and nature of the tumor. Ultrasound (US) is useful as an initial test and, if necessary, can lead directly to an ultrasound-guided biopsy. CT helps assess the extent of the tumor, the possibility of bone invasion, and the lymph nodes. MRI provides good soft tissue contrast and has strengths in evaluating invasion of nerves or surrounding tissue. If malignancy is strongly suspected or the lesion is advanced, additional tests such as chest CT may be performed to check for distant metastasis.
The key to confirming the diagnosis is biopsy. Fine-needle aspiration (FNA) collects cells with a thin needle, can be performed relatively easily, and tends to have few complications. Core needle biopsy (CNB) obtains more tissue and can increase accuracy, but it is chosen after considering the risk of bleeding and the distance to nerves and blood vessels. In the end, the tumor type and degree of malignancy are often confirmed by pathological examination of the tissue removed at surgery.
Treatment
Treatment varies depending on whether the tumor is benign or malignant, where it is located, and its size and extent. Because there are many types of salivary gland tumors, they are not "all solved with one treatment," but in many cases surgery is the center of treatment. For benign parotid tumors, because the risk of recurrence can increase with an approach that cuts out only the tumor, surgery that removes the tumor together with part of the surrounding gland tissue is considered. One of the most important goals here is preserving the facial nerve. The extent is determined with preoperative imaging, and intraoperative nerve monitoring is sometimes used to reduce the risk of nerve damage.
For malignant tumors, the extent of surgery may be wider, and if there is invasion of surrounding tissue, it is removed as well. If lymph node metastasis is suspected or the risk is high, neck lymph node surgery may be performed at the same time. Radiation therapy is commonly added after surgery, with the aim of reducing any cancer cells that may remain and lowering the risk of recurrence. For advanced or metastatic tumors, chemotherapy may be considered, and for some tumors, targeted therapy or immunotherapy may be chosen according to molecular markers.
Management after treatment is also important. Decreased facial nerve function, dry mouth due to decreased saliva secretion, difficulty chewing and swallowing, surgical scars, and mucosal dryness after radiation therapy can become problems, so rehabilitation and oral care are needed. In particular, because persistent dry mouth raises the risk of tooth decay and gum disease, fluid intake, artificial saliva, oral hygiene, and dental care are helpful.
Prognosis
The prognosis depends greatly on the type (subtype) of the tumor, its stage (how far it has spread), and how completely treatment was carried out. Benign tumors generally have a good prognosis when removed with appropriate surgery. However, even benign tumors can recur if incompletely removed, and if recurrence is repeated, surgery becomes more complicated and the risk of facial nerve damage can also increase. Therefore, "the quality of the initial treatment" can have an important effect on prognosis.
Malignant tumors vary greatly in course by subtype. Some tumors progress relatively slowly and respond well to treatment, but there are also tumors with a strong tendency to spread along nerves (perineural invasion) or that readily develop lymph node and distant metastases. Factors cited as worsening the prognosis include rapid growth, facial nerve paralysis, skin infiltration, lymph node metastasis, distant metastasis, high-grade (more aggressive cells) pathological findings, and a location that makes complete surgical removal difficult.
Because salivary gland cancer is closer to a group of several diseases than to "a single disease," it is difficult to determine an individual's prognosis with a single number. After diagnosis, it is necessary to receive an explanation of one's individual risk based on the combined pathology and imaging results and to establish a follow-up testing plan. Even after treatment ends, long-term follow-up that checks not only for recurrence but also facial nerve function, dry mouth, and chewing and swallowing function for a certain period is important.
Prevention
Methods of reliably preventing salivary gland tumors are limited. In many cases the cause is difficult to identify, so it is hard to say they can be prevented with a particular diet or supplements alone. Nevertheless, there are practices that may reduce the risk. First, reducing unnecessary radiation exposure helps. It is important to receive necessary medical imaging appropriately, but it is best to avoid repeated tests that are not really necessary. Second, because smoking has been reported to be associated with some salivary gland tumors, quitting smoking helps in many ways. Third, if one works in an environment with occupational exposure to dust and chemicals, wearing protective equipment and following safety rules are important.
Realistically, the most important "prevention" is early detection. Seeking medical care quickly when a new lump below the ear or under the jaw does not go away for 2 weeks or more or grows larger, when it is accompanied by pain, sensory abnormalities, or skin changes, or when facial asymmetry newly develops, is meaningful for improving treatment outcomes in malignant tumors. In other words, secondary prevention (early diagnosis), which means not missing warning signs, has greater significance in daily life than perfect primary prevention (preventing the occurrence itself).